Biocon’s Malaysian facility will unveil in FY15

Biocon, on January 22, 2014, officially announced its quarterly performance and highlights for 9MFY14, witnessing 16% growth led by its research services and branded formulations.


Dr Kiran Mazumdar-Shaw, CMD, Biocon

According to the company's statement, Biocon's revenues touched Rs 2,187 crore, EBITDA stood at Rs 550 crore and PAT at Rs 301 crore.

In her comments, Biocon's CMD Dr Kiran Mazumdar-Shaw, revealed that the company's investment efforts in building its insulin facility in Malaysia is on track and that it will be unveiled in FY15.

Commenting on the occasion, Dr Kiran Mazumdar-Shaw stated, "Q3 FY14 has been a very eventful quarter for us, with several research milestones across our novel molecules and biosimilars portfolio. The key highlight was the DCGI approval for our biosimilar Trastuzumab, which paved the way for its commercial launch in India as CANMAb."

CANMAb was launched in Bangalore, India, on January 18, 2014, as the world's first biosimilar Trastuzumab.

According to the press release, Biocon's biopharmaceuticals segment has been steady with 14% YoY. "We have witnessed sustained business momentum in research services (35% YoY), and a return to growth for our branded formulations vertical. We expect to close this financial year with a strong performance across business verticals," expressed Dr Kiran.


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email